Division of vascular Surgery, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Division of vascular Surgery, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy.
J Vasc Surg. 2023 Jun;77(6):1598-1606.e3. doi: 10.1016/j.jvs.2023.02.007. Epub 2023 Feb 22.
To investigate the technical periprocedural and midterm outcomes of endovascular repairs with multibranched endovascular repair or iliac branch devices combined with a new self-expanding covered stent.
The COvera in BRAnch registry is a physician-initiated, multicenter, ambispective, observational registry (ClinicalTrials.gov Identifier: NCT04598802) enrolling patients receiving a multibranched endovascular repair or iliac branch devices procedure mated with Bard Covera Plus (Tempe, AZ) covered stent, designed to evaluate the outcomes of the covered stent mated with patient-specific and off-the-shelf branched stent graft. Primary end points were technical success, branch instability, and freedom from aortic and branch-related reintervention within 30 days and at follow-up. Preoperative characteristics, comorbidities, and outcomes definitions were graded according to the Society for Vascular Surgery reporting standards.
Two hundred eighty-four patients (76 years; range, 70-80 years; 79% males) in 24 centers were enrolled for a total of 708 target vessels treated. The covered stents were mated with an off-the-shelf graft in 556 vessels (79%) and a custom-made graft in 152 (21%). Three hundred seven adjunctive relining stents in 277 vessels (39%) were deployed, of which 116 (38%) were proximal, 66 (21%) intrastent, and 125 (41%) distal. Adjunctive relining stent placement was more frequent when landing in a vessel branch instead of the main trunk (59% vs 39%; P = .031), performing a percutaneous access (49% vs 35%; P < .001), using a stent with a diameter of 8 mm or greater (44% vs 36%; P = .032) and a length of 80 mm or greater (65% vs 55%; P = .005), when a post-dilatation was not performed (45% vs 29%; P < .001) and when an inner branch configuration was used (55% vs 35%; P < .001). Perioperative technical bridging success was 98%. Eight patients (3%) died in the perioperative period. Two deaths (1%) were associated with renal branch occlusion followed by acute kidney injury and paraplegia. Follow-up data were available for 638 vessels (90%) at a median of 32 months (Q1, Q3, 21, 46). Branch instability was reported in 1% of branches. Forty-six patients (17%) died during follow-up, nine (3%) of them owing to aortic-related causes. Primary patency rates at 1, 2, and 3 years were 99% (581/587), 99% (404/411), and 97% (272/279), respectively. Branch instability was associated with patient-specific devices (9% vs 4%; P = .014) and intrastent adjunctive stent placement (12% vs 2%; P = .003), especially when a bare metal balloon-expandable stent was used (25% vs 3%; P < .001).
The use of this new self-expanding covered stent mated with branched endografts proved to be safe and feasible with high technical procedural success rates. Low rates of branch instability were observed at midterm follow-up. Comparative studies with other commercially available covered stents are warranted.
研究使用多分支血管内修复或髂内分支装置联合新型自膨式覆膜支架进行血管内修复的围手术期技术和中期结果。
COvera in BRAnch 注册研究是一项由医师发起的、多中心、前瞻性、观察性注册研究(ClinicalTrials.gov 标识符:NCT04598802),纳入接受多分支血管内修复或髂内分支装置与 Bard Covera Plus(Tempe,AZ)覆膜支架联合治疗的患者,旨在评估覆膜支架与患者特异性和现货分支支架移植物联合的结果。主要终点是 30 天内和随访时的技术成功率、分支不稳定和免于主动脉和分支相关再干预。术前特征、合并症和结局定义根据血管外科学会报告标准进行分级。
在 24 个中心共招募了 284 例(76 岁;范围 70-80 岁;79%为男性)患者,共治疗了 708 个靶血管。覆膜支架与现货分支移植物联合使用 556 个血管(79%),与定制分支移植物联合使用 152 个血管(21%)。在 277 个血管(39%)中部署了 307 个辅助再衬支架,其中 116 个(38%)为近端支架,66 个(21%)为支架内支架,125 个(41%)为远端支架。在分支内植入(59%比 39%;P =.031)、经皮入路(49%比 35%;P <.001)、使用直径 8mm 或更大的支架(44%比 36%;P =.032)和长度 80mm 或更长的支架(65%比 55%;P =.005)、未进行后扩张(45%比 29%;P <.001)和使用内分支构型(55%比 35%;P <.001)时,更频繁地放置辅助再衬支架。围手术期技术桥接成功率为 98%。8 例(3%)患者在围手术期死亡。2 例(1%)死亡与肾分支闭塞后急性肾损伤和截瘫有关。中位随访 32 个月(Q1、Q3、21、46)时,638 个血管(90%)有随访数据。1%的分支出现分支不稳定。46 例(17%)患者在随访期间死亡,其中 9 例(3%)死于主动脉相关原因。1、2、3 年的主要通畅率分别为 99%(581/587)、99%(404/411)和 97%(272/279)。分支不稳定与患者特异性装置(9%比 4%;P =.014)和支架内辅助支架放置(12%比 2%;P =.003)有关,尤其是使用裸金属球囊扩张支架时(25%比 3%;P <.001)。
使用这种新型自膨式覆膜支架与分支内移植物联合使用,证明是安全可行的,具有较高的技术手术成功率。中期随访发现分支不稳定发生率较低。需要与其他市售的覆膜支架进行比较研究。